Innovations in CRISPR advancing translational research
13 Sep 2021
Over the past decade, CRISPR has proven itself a versatile and efficient tool for gene editing and modification. Its potential as a therapeutic agent is clear, but the current offerings lack the appropriate quality and consistency characteristics to realize this potential. To address this gap, Sigma-Aldrich® is introducing the new PURedit™ CRISPR reagents, specifically suited for preclinical and translational research.
PURedit™ Cas9 is a novel variant that is designed with the key features of wild type and eSpCas9 combined – high activity and high on-target specificity. In addition, PURedit™ synthetic sgRNAs are HPLC-purified to achieve the highest purity and quality. Their combination into an RNP complex aims to provide a highly efficient and consistent gene editing platform for therapeutic research, enabling researchers to move their therapies into the clinic faster.
Key learning objectives
- Explore the key requirements of CRISPR reagents for preclinical and translational research
- Understand performance and quality characteristics of gene editing reagents that make them ideal for preclinical research
- Learn how CRISPR reagents can be used in a variety of applications to provide enhanced-specificity without sacrificing cutting activity
Who should attend?
- Scientists from pharma, biotech, and academic institutions using gene editing for discovery or preclinical research.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes